# Proximity labeling in neuroscience: decoding molecular landscapes for precision neurology

**Authors:** Xia Gao, Jianjun Lu, Peipei Chen, Xinna Wang, Longlong Zheng, Yuyin Shao, Huali Shen, Qian Yang

PMC · DOI: 10.1186/s40035-026-00534-8 · 2026-01-29

## TL;DR

Proximity labeling helps map molecular interactions in the nervous system, offering new insights into neurological diseases and potential treatments.

## Contribution

This review systematically outlines how proximity labeling technologies transform molecular neuroscience and precision neurology.

## Key findings

- Proximity labeling enables high-resolution mapping of proteomes and interactomes in specific neural compartments.
- PL technologies are advancing understanding of diseases like Alzheimer’s and Parkinson’s by revealing pathophysiological mechanisms.
- Integration of PL with multi-omics and single-cell methods could enhance precision neurology and drug discovery.

## Abstract

The intricate cellular architecture and dynamic molecular interplay in the nervous system have long challenged mechanistic studies of neurological diseases. Conventional approaches often miss the transient, low-affinity, or spatially confined interactions that underlie neural homeostasis and pathogenesis. Proximity labeling (PL) technologies overcome this limitation by enabling in situ capture of these elusive molecular events within living systems. Through spatially restricted biotinylation, PL methods, including engineered biotin ligases (e.g., TurboID), peroxidases (e.g., APEX2), and emerging photocatalytic platforms, allow high-resolution mapping of proteomes and interactomes within defined subcellular compartments, cell types, and cell-cell interfaces. In this review, we systematically outline the principles of PL and its transformative applications in constructing molecular atlases of the nervous system. We highlight how these tools are revolutionizing our understanding of brain function by elucidating pathophysiological mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurological disorders. Furthermore, we discuss how PL accelerates the translation of basic research into clinical practice by facilitating the discovery of mechanistic biomarkers and druggable targets. Finally, we address current challenges and future directions, including integration with multi-omics and single-cell methodologies, and conclude that PL can advance precision neurology by bridging molecular neurobiology with therapeutic innovation.

## Linked entities

- **Proteins:** APEX2 (apurinic/apyrimidinic endodeoxyribonuclease 2)
- **Diseases:** Alzheimer’s disease (MONDO:0004975), Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** NCAN (neurocan) [NCBI Gene 1463] {aka CSPG3}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, SNW1 (SNW domain containing 1) [NCBI Gene 22938] {aka Bx42, FUN20, NCOA-62, PRPF45, Prp45, SKIIP}, SCAMP3 (secretory carrier membrane protein 3) [NCBI Gene 10067] {aka C1orf3}, Adnp (activity-dependent neuroprotective protein) [NCBI Gene 11538] {aka mKIAA0784}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, LAMP2 (lysosome associated membrane protein 2) [NCBI Gene 3920] {aka CD107b, DND, LAMP-2, LAMPB, LGP-96, LGP110}, CRYAB (crystallin alpha B) [NCBI Gene 1410] {aka CMD1II, CRYA2, CTPP2, CTRCT16, HEL-S-101, HSPB5}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, NUFIP2 (nuclear FMR1 interacting protein 2) [NCBI Gene 57532] {aka 182-FIP, 82-FIP, FIP-82, NUFP2, PIG1}, AURKB (aurora kinase B) [NCBI Gene 9212] {aka AIK2, AIM-1, AIM1, ARK-2, ARK2, AurB}, Gphn (gephyrin) [NCBI Gene 268566] {aka 5730552E08Rik, C230040D23, GPH, GPHRYN, geph}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, MBP (myelin basic protein) [NCBI Gene 4155], PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, Bace1 (beta-site APP cleaving enzyme 1) [NCBI Gene 23821] {aka ASP2, Bace}, Dlg4 (discs large MAGUK scaffold protein 4) [NCBI Gene 13385] {aka Dlgh4, PSD-95, PSD95, SAP90, SAP90A}, Gjd2 (gap junction protein, delta 2) [NCBI Gene 14617] {aka Cxns, Gja9, connexin36, cx36}, SYNJ2BP (synaptojanin 2 binding protein) [NCBI Gene 55333] {aka ARIP2, OMP25}, SSU72 (SSU72 homolog, RNA polymerase II CTD phosphatase) [NCBI Gene 29101] {aka HSPC182, PNAS-120}, TBC1D5 (TBC1 domain family member 5) [NCBI Gene 9779], TERC (telomerase RNA component) [NCBI Gene 7012] {aka DKCA1, PFBMFT2, SCARNA19, TER, TR, TRC3}, NRXN1 (neurexin 1) [NCBI Gene 9378] {aka Hs.22998, PTHSL2, SCZD17}, ANXA11 (annexin A11) [NCBI Gene 311] {aka ALS23, ANX11, CAP-50, CAP50, IBMWMA}, POLA1 (DNA polymerase alpha 1, catalytic subunit) [NCBI Gene 5422] {aka NSX, PDR, POLA, VEODS, p180}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, CTTN (cortactin) [NCBI Gene 2017] {aka EMS1}, PDLIM7 (PDZ and LIM domain 7) [NCBI Gene 9260] {aka LMP1, LMP3}, LBR (lamin B receptor) [NCBI Gene 3930] {aka C14SR, DHCR14B, LMN2R, PHA, PHASK, TDRD18}, TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, RTN4IP1 (reticulon 4 interacting protein 1) [NCBI Gene 84816] {aka NIMP, OPA10, Yim1}, VCP (valosin containing protein) [NCBI Gene 7415] {aka CDC48, FTDALS6, TERA, p97}, C9orf72 (C9orf72-SMCR8 complex subunit) [NCBI Gene 203228] {aka ALSFTD, DENND9, DENNL72, FTDALS, FTDALS1}, HBB (hemoglobin subunit beta) [NCBI Gene 3043] {aka CD113t-C, ECYT6, beta-globin}, PFN1 (profilin 1) [NCBI Gene 5216] {aka ALS18, PDB7}, CADM1 (cell adhesion molecule 1) [NCBI Gene 23705] {aka BL2, IGSF4, IGSF4A, NECL2, Necl-2, RA175}, Sipa1l3 (signal-induced proliferation-associated 1 like 3) [NCBI Gene 74206] {aka 2610511M17Rik}, Camk2a (calcium/calmodulin-dependent protein kinase II alpha) [NCBI Gene 12322] {aka CaMKII, mKIAA0968}, VPS35 (VPS35 retromer complex component) [NCBI Gene 55737] {aka MEM3, PARK17}, Ctcf (CCCTC-binding factor) [NCBI Gene 13018], Eif2ak3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 13666] {aka Pek, Perk}, Apex2 (apurinic/apyrimidinic endonuclease 2) [NCBI Gene 77622] {aka C430040P13Rik, ape2}, U2AF2 (U2 small nuclear RNA auxiliary factor 2) [NCBI Gene 11338] {aka DEVDFB, U2AF65}, STMN2 (stathmin 2) [NCBI Gene 11075] {aka SCG10, SCGN10}, NLGN3 (neuroligin 3) [NCBI Gene 54413] {aka HNL3}, CBR1 (carbonyl reductase 1) [NCBI Gene 873] {aka CBR, PG-9-KR, SDR21C1, hCBR1}, Pvalb (parvalbumin) [NCBI Gene 19293] {aka PV, Parv, Pva}, HNRNPC (heterogeneous nuclear ribonucleoprotein C) [NCBI Gene 3183] {aka HNRNP, HNRPC, MRD74, SNRPC}, Nsf (N-ethylmaleimide sensitive fusion protein) [NCBI Gene 18195] {aka SKD2}, G3BP1 (G3BP stress granule assembly factor 1) [NCBI Gene 10146] {aka G3BP, HDH-VIII}, SNAR-E (small NF90 (ILF3) associated RNA E) [NCBI Gene 100170220], PARK7 (Parkinsonism associated deglycase) [NCBI Gene 11315] {aka DJ-1, DJ1, GATD2, HEL-S-67p}, HSD17B6 (hydroxysteroid 17-beta dehydrogenase 6) [NCBI Gene 8630] {aka HSE, RODH, SDR9C6}, EMP3 (epithelial membrane protein 3 (MAM blood group)) [NCBI Gene 2014] {aka YMP}, RRBP1 (ribosome binding protein 1) [NCBI Gene 6238] {aka ES/130, ES130, RRp, hES, p180}, APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) [NCBI Gene 328] {aka APE, APE1, APEN, APEX, APX, HAP1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, APEX2 (apurinic/apyrimidinic endodeoxyribonuclease 2) [NCBI Gene 27301] {aka APE2, APEXL2, XTH2, ZGRF2}, MDGA2 (MAM domain containing glycosylphosphatidylinositol anchor 2) [NCBI Gene 161357] {aka DEE122, MAMDC1, c14_5286}
- **Diseases:** synaptic dysfunction (MESH:C536122), inflammatory (MESH:D007249), FTLD (MESH:D057174), ALS (MESH:D000690), PD (MESH:D010300), neurological disorder (MESH:D009461), AD (MESH:D000544), memory loss (MESH:D008569), amyloid (MESH:C000718787), CBD (MESH:D000088282), PL (MESH:D014897), tauopathies (MESH:D024801), frontotemporal dementia (MESH:D057180), tumor (MESH:D009369), neuronal death (MESH:D009410), DLB (MESH:D020961), epilepsy (MESH:D004827), neurological disease (MESH:D020271), ASD (MESH:D000067877), neurodevelopmental disorders (MESH:D002658), toxicity (MESH:D064420), vesicular and mitochondrial dysfunction (MESH:D028361), neurodegeneration (MESH:D019636), brain cancers (MESH:D001932), GBM (MESH:D005909), neuropsychiatric disorders (MESH:D001523), MSA (MESH:D019578), synucleinopathies (MESH:D000080874), neuroinflammation (MESH:D000090862)
- **Chemicals:** dibenzylfluorescein (MESH:C558664), paraffin (MESH:D010232), carbenes (MESH:C030011), LPS (MESH:D008070), H2O2 (MESH:D006861), histidine (MESH:D006639), phenoxy radicals (MESH:C042329), iridium (MESH:D007495), acids (MESH:D000143), Eosin Y (MESH:D004801), lysine (MESH:D008239), ATP (MESH:D000255), tyrosine (MESH:D014443), 5xFAD (-), cysteine (MESH:D003545), nitrenes (MESH:C017621), coenzyme Q (MESH:D014451), peroxide (MESH:D010545), biotin (MESH:D001710), hydrocarbon (MESH:D006838), lipid (MESH:D008055), rhodamine 123 (MESH:D020112), calcium (MESH:D002118), formalin (MESH:D005557), singlet oxygen (MESH:D026082), quinone methide (MESH:C068040), tryptophan (MESH:D014364), ruthenium (MESH:D012428), azide (MESH:D001386), phosphatidylethanolamine (MESH:C483858), phosphoinositide (MESH:D010716)
- **Species:** Homo sapiens (human, species) [taxon 9606], Drosophila melanogaster (fruit fly, species) [taxon 7227], Mus musculus (house mouse, species) [taxon 10090], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Danio rerio (leopard danio, species) [taxon 7955]
- **Mutations:** C71G, A53T, M114T, G93A, G85R, A-to-I
- **Cell lines:** BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HT22 — Mus musculus (Mouse), Transformed cell line (CVCL_0321)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12853706/full.md

---
Source: https://tomesphere.com/paper/PMC12853706